We create innovative treatments for nervous system damage due to injury or disease.
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company creating innovative treatments that enable the nervous system to repair itself following damage. NervGen’s lead drug candidate, NVG-291 is currently in a Phase 1 clinical trial. The company’s initial target indications are spinal cord injury, Alzheimer’s disease and multiple sclerosis.
View our Corporate Presentation
Subscribe to our mailing list to stay up to date
February 14, 2023
NervGen announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical trial of the Company’s proprietary lead compound, NVG-291, have completed dosing.
July 28, 2022
Unlike existing treatments that focus on rehabilitation or reducing the risk of an additional stroke, the experimental drug targets the "stickiness" that can prevent injured brain tissue from functioning as it should
February 15, 2023
NervGen Pharma Corporate Update with Bill Radvak and Torrey Hills Capital. Click below to watch.